Form 4: Oramed Pharmaceuticals CEO Nadav Kidron Acquires 45,000 Shares
SEC Form 4
Oramed Pharmaceuticals CEO Nadav Kidron reports acquiring 45,000 shares of common stock and holding 1,826,098 shares directly, along with 126,000 shares indirectly through a wholly-owned corporation.
Summary
- On November 7, 2024, Nadav Kidron, the President and CEO of Oramed Pharmaceuticals Inc., acquired 45,000 shares of the company's common stock.
- Following this transaction, Kidron directly owns 1,826,098 shares of Oramed Pharmaceuticals.
- Kidron also indirectly owns 126,000 shares through a wholly-owned corporation.
- The acquisition involved Restricted Stock Units (RSUs) that vested on November 7, 2024, and convert into common stock on a one-for-one basis.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by the CEO. While insider buying can be seen as a positive signal, it's not overwhelmingly positive without more context.
Positives
- The CEO's acquisition of shares may signal confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored as they can provide insights into management's perspective on the company's valuation and future performance.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive sign.
Key Dates
| Date | Description |
|---|---|
| 11/07/2024 | Date of transaction: Nadav Kidron acquired 45,000 shares of Oramed Pharmaceuticals common stock and RSUs vested. |
| 11/08/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.